Prescient Therapeutics
Follow
Get notifications in MyBN when activity occurs.
Industry Lists
Public Companies - non WAPrescient Therapeutics Limited (PTX) is a clinical stage oncology company developing novel compounds that show potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy. The company continues to develop its two drug candidates, PTX-100 and PTX-200, for potential new therapies to treat a range of cancers, including breast and ovarian cancer, as well as leukaemia.
Contact Details
Level 4, 100 Albert Rd, SOUTH MELBOURNE VIC 3205
03 9692 7222
Lists and Charts
Share Price
Closing price for the last 90 trading days
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| th |  | Prescient Therapeutics | $1.2m |
1339 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Total Shareholder Return as at 29/07/22
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 791st | Prescient Therapeutics | -7% | 30% |
1842 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Company Activity
| NEWS: Tagged in Where markets meet medicine; a biotech entrepreneur at the tip of the spear | 14 Feb 2022 |
| NEWS: Tagged in Radiopharm scores coup with rare isotope supply deal | 01 Feb 2022 |
| NEW ROLE: Said Sebti, Chief Scientific Officer | 24 Nov 2020 |
| NEW ROLE: Terrence Chew, Chief Medical Officer | 24 Nov 2020 |
| NEW ROLE: Said Sebt, | 24 Nov 2020 |
| NEW ROLE: Allen J Ebens, Non-Executive Director | 03 Nov 2020 |
| NEW ROLE: Melanie Leydin, Company Secretary | 03 Nov 2020 |
